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Abstract: The present study evaluated the antidiabetic activity of the Combretum 
lanceolatum Pohl ex Eichler, Combretaceae, flowers extract (ClEtOH) in diabetic 
rats. Streptozotocin-diabetic rats were divided into four groups: diabetic control, 
diabetic treated with 500 mg/kg of metformin and diabetic treated with 250 or 500 
mg/kg of ClEtOH for 21 days. The treatment of diabetic rats with 500 mg/kg of 
ClEtOH promoted an increase in the weight of liver, white adipose tissues and 
skeletal muscles, improving body weight gain. Diabetic rats treated with 500 mg/kg 
of ClEtOH also presented reduction in glycemia, glycosuria and urinary urea levels, 
and increase in liver glycogen content. HPLC chromatogram showed that quercetin 
is the major compound in the extract. The phosphorylation levels of adenosine 
monophosphate-activated protein kinase were increased in liver slices incubated in 
vitro with 50 μg/mL of ClEtOH, similarly to the incubation with metformin (50 μg/
mL) or quercetin (10 μg/mL). The antihyperglycemic effect of ClEtOH was similar 
to that of metformin and appears to be through inhibition of gluconeogenesis, 
since urinary urea was reduced and skeletal muscle mass was increased. These 
data indicate that the antidiabetic activity of the Combretum lanceolatum extract 
could be mediated, at least in part, through activation of adenosine monophosphate-









 Diabetes mellitus, a chronic metabolic disease 
characterized by a defi ciency in the pancreas insulin 
production and/or by peripheral insulin resistance, can 
be referred as a global epidemic disease; data from the 
World Health Organization (WHO) estimate that this 
disorder affected 285 million people worldwide in 2010 
and projections rise to 439 million in 2030 (Shaw et al., 
2010). In Brazil, diabetes mellitus appeared as one of 
the ten main causes of deaths in Brazil in 2002 (WHO, 
2006). Schmidt and collaborators (2011) have shown that 
the prevalence of diabetes in Brazil has been rising in 
association to obesity and to increased western diet and 
physical inactivity, affecting 5.3 % of Brazilians aged 20 
years or older in 2008, in comparison to 3.3 % in 1998.
 The adverse effects of hypoglycemic drugs 
and insulin and the excessive cost of these medications 
can be mentioned as some disadvantages regarding the 
diabetes treatment, which stimulate the search for new 
therapeutic agents that present safety, effectiveness and 
low cost. Nowadays, there is growing trend towards using 
herbal preparations and/or derivatives in traditional and 
complementary medicine to treat diabetes symptoms (Yeh 
et al., 2003). In this way, it has been crescent the interest of 
current ethnopharmacological research to investigate the 
plants species with antihyperglycemic effect, focusing in the 
evaluation of the effi cacy and safety of plant preparations 
for diabetes treatment, as well as the mechanisms of action 
that explain their antidiabetic activities (Kawashita & 
Baviera, 2010; Prabhakar & Doble, 2011).
 Combretum lanceolatum Pohl ex Eichler, 
Combretaceae, commonly known as “pombeiro-vermelho”, 
is distributed from northern to southeastern of Brazil and 
is found in several phytogeographic domains including 
Amazon, Pantanal, Caatinga, Cerrado and Atlantic Forest 
(Marquete & Valente, 2010). Ethnopharmacological 
studies have demonstrated that plants from Combretum 
genus presented antidiabetic activity. The six weeks 
treatment of streptozotocin-diabetic rats with ethanolic 
extract of Combretum decandrum Jacq. leaves decreased 
fasting blood glucose levels (Pannangpetch et al., 
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2008). Chika & Bello (2010) showed that Combretum 
micranthum G. Don leaves aqueous extract treatment 
improved glucose tolerance and reduced fasting glycemia 
in both normal and alloxan-diabetic rats. The treatment of 
streptozotocin-diabetic rats with mollic acid glucoside, a 
hydroxycycloartenoid isolated from leaves of Combretum 
molle R. Br. ex G. Don, reduced glycemia levels in a dose-
dependent manner (Ojewole & Adewole, 2009). Phenolic 
compounds, especially flavonoids, are widely reported in 
Combretum genus, and they are probably the responsible 
for its antihyperglycemic activity (Eloff et al., 2004; 
Lopes et al., 2010). These findings stimulate the present 
study, since there is no systematic study attempting to the 
investigation of the antidiabetic activity of C. lanceolatum, 
one of the most important species of Combretaceae in 
the Brazilian Pantanal (Pott et al., 2011). In this way, 
our laboratory initiated the evaluation of the antidiabetic 
properties of several parts (flowers, fruits, leaves) of this 
plant, attempting to its further indication in phytotherapic 
formulations. The present study was undertaken to assess 
the subchronic antidiabetic activity of the C. lanceolatum 
flowers ethanolic extract (ClEtOH) in streptozotocin-
diabetic rats.
Materials and Methods
Plant material collection and preparation of the ClEtOH 
extract
 Flowers of Combretum lanceolatum Pohl ex 
Eichler, Combretaceae, were collected in Poconé Porto 
Cercado road (km 10), Poconé-MT, Brazil (S 16º18'56.4"; 
W 056°32'21.5"; 126 m of elevation) in July 2010. The 
access to plant samples was authorized by Conselho de 
Gestão do Patrimônio Genético of Ministério do Meio 
Ambiente (license numbers 010457/2010-0). The plant 
material was identified by Dr. Germano Guarim Neto, 
Central Herbarium, Universidade Federal de Mato Grosso, 
where a voucher specimen (numbers 39,149) was deposited 
for future reference. The flowers of C. lanceolatum were 
dried at room temperature and grounded in electric grinder. 
Later, 5,960 kg of the botanical material was placed 
in maceration with ethanol at room temperature under 
occasional shaking, in seven cycles of seven days. The 
mixture was then filtered and concentrated on the rotary 
evaporator at reduced pressure and 38 ºC approximately, 
obtaining the crude ethanol extract of C. lanceolatum - 
ClEtOH (2,350 kg; 39.43 % w/w).
Preparation of sample solutions
 Quercetin (Riedel-de Haën, Germany) standard 
stock solution and ClEtOH stock solution were prepared 
in methanol (1.0 mg/mL and 5.0 mg/ml respectively). For 
the sample fortification quercetin and ClEtOH methanol 
solutions were mixed in the ratio of 2:1. All sample 
solutions were filtered through 0.45 μm membrane filter 
(Millipore, USA), and injected directly into the HPLC-UV 
for analysis.
Chromatographic analysis
 High performance liquid chromatographic 
analyses were carried out on a Varian ProStar liquid 
chromatograph, equipped with binary gradient pumping 
and a ProStar 325 Dual Wavelength UV-Vis Detector 
(Varian). A HICHROM 5C18 reversed-phase column (ø 
4.6 mm×250 mm) packed with 5 μm diameter particles 
with a Kromasil® 100-5C18 guard column (4.6 mm×10 
mm i.d., 5 μm) was employed. As the mobile phase, a 
gradient of methanol-water containing 0.1% trifluoroacetic 
acid (50-80% in 35 min) was employed. The detections 
were performed at 368 nm. Flow rate and injection volume 
were 0.5 mL/min and 10 μL, respectively. The presence of 
quercetin was confirmed by comparing its retention time 
and by fortification of the extract with standard quercetin. 
All chromatographic operations were carried out at ambient 
temperature.
 Classical column chromatography on silica gel 
and preparative thin layer chromatography were performed 
in ClEtOH, affording the isolation of quercetin, among 
other flavonoids, as a majoritary compound. The details 
will be published elsewhere (Araujo, 2012).
NMR analyses
 NMR analyses were recorded in CD3OD, using 
TMS as internal standard in a Bruker spectrometer (500 
MHz for 1H and 125 MHz for 13C).  
Animals
 Male Swiss-Webster mice weighing 25-30 g 
(acute toxicity study) and male Wistar rats weighing 180-
210 g (subchronic antidiabetic activity) were housed in 
a room under standard laboratory conditions (12:12 h 
light-dark cycle, 24±1 °C) and had free access to water 
and commercial lab chow diet (Purina®Labina). During 
the experiments of the antidiabetic activity, rats were 
housed in individual metabolic cages. All experiments 
took place between 8 and 10 am. Experimental procedures 
were made according to the Brazilian College of Animal 
Experimentation and received prior institutional approval 
by the Committee for Ethics in Animal Experimental from 
UFMT (protocol number 23108.029613/09-3).
Acute oral toxicity study (Hippocratic test)
 Groups of male mice received orally by gavage 
a single administration of ClEtOH at crescent doses 
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(100; 250; 500; 1,000; 2,500 and 5,000 mg/kg). The 
control group received vehicle (water). The animals were 
individually observed at 0, 5, 10, 15, 30 min; 1, 2, 4 and 8 
h and after four and fifteen days (once a day) following the 
extract administration. General behavioral observations 
were noted in the table described by Malone (1977).
Subchronic evaluation of extract in streptozotocin-induced 
diabetic rats
 Streptozotocin (STZ, 40 mg/kg) dissolved in 0.01 
mol/L citrate buffer (pH 4.5) was administered through a 
single intravenous injection in 15 h fasted rats. Five days 
after STZ administration, rats with glycemia levels of 
approximately 400 mg/dL were selected to the experiments 
and randomly assigned into four groups: DC, diabetic 
control rats treated with vehicle (water); DMet, diabetic rats 
treated with 500 mg/kg of metformin; DT250, diabetic rats 
treated with 250 mg/kg of ClEtOH; DT500, diabetic rats 
treated with 500 mg/kg of ClEtOH. The groups received 
vehicle, metformin or freshly prepared extract by oral 
gavage for 21 days. Body weight, food and water intake 
and urinary volume were daily monitored. At every five 
days, plasma glucose levels were determined (Bergmeyer 
et al., 1974), as well as the urea (Bernt & Bergmeyer, 
1965) and glucose urinary levels (Summerson et al., 1947) 
in 24 h urine. At the end of the treatment, white adipose 
tissues (retroperitoneal, perirenal and epididymal), skeletal 
muscles (soleus and extensor digitorum longus - EDL) 
and liver were removed and weighted. Liver glycogen was 
extracted with 30% KOH and precipitated with ethanol 
(Sjörgren et al., 1938) and the quantity recovered was 
measured by colorimetric phenol-sulfuric acid method 
(Montgomery, 1957). 
Incubation procedure and Western blotting analysis
 Measurement of the adenosine monophosphate-
activated protein kinase (AMPK) activation was 
performed in liver slices incubated in vitro in the presence 
of ClEtOH, quercetin or metformin. Rats were killed, liver 
was rapidly dissected and uniform-shaped liver slices 
(1 mm thick) were obtained from the right lobe with a 
tissue chopper (Dogterom, 1993; Bach et al., 1996). Liver 
slices were incubated during 1 h at 37 oC in Krebs-Ringer 
bicarbonate buffer (pH 7.4) equilibrated with 95% O2/5% 
CO2 and containing glucose (5 mM) in the absence (basal 
sample) or in the presence of ClEtOH (50 and 100 μg/
mL), quercetin (10 and 50 μg/mL) or metformin (10 and 
50 μg/mL). After incubation, tissues were immediately 
frozen in liquid nitrogen before Western blotting analysis. 
Following, tissues were homogenized in 50 mM Tris-HCl 
buffer (pH 7.4) containing 150 mM NaCl, 1 mM EDTA, 
1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS), 10 
mM sodium pyrophosphate, 100 mM sodium fluoride, 10 
mM sodium orthovanadate, 5 μg/mL aprotinin and 1 mM 
phenylmethylsulfonyl fluoride; supernatants samples were 
used for protein levels determination (Bradford, 1976) and 
for electrophoresis separation. Samples (100 μg of protein) 
were subjected to SDS-PAGE analysis on 10% acrylamide 
gels (Laemmli, 1970). Gels were electroblotted onto 
nitrocellulose membranes (Towbin et al., 1979) and blotted 
with anti-AMPKα (1:1,000, Cell Signaling Technology, 
USA) and anti-phospho-[Thr172]-AMPKα (1:1,000, 
Cell Signaling Technology, USA). Primary antibody was 
detected by peroxidase-conjugated secondary antibody 
(1:7,500, Santa Cruz Biotechnology, USA) and visualized 
with SuperSignal West Pico chemiluminescent substrate 
(Pierce Biotechnology, USA). Band intensities were 
quantified using the ImageJ Program (Version 1.38, 
National Institutes of Health, USA, 2004).
Statistical analysis
 Data were expressed as mean±SEM. One-
way analysis of variance followed by Tukey’s multiple 
comparison tests was used to analyze the differences 
between treated and control groups. Unpaired t test was 
used to compare the means of AMPK phosphorylation 
values from liver slices incubated under different conditions 
with basal sample. Differences were considered significant 
at p<0.05 and p<0.01.
Results
Isolation and identification of quercetin in ClEtOH
 The HPLC chromatogram (Figure 1A-C) has 
shown that the flavonoid quercetin seems to be the major 
compound in ClEtOH, and its presence was evidenced 
by fortification with standard quercetin solution, through 
the increase in peak area at 18.365 min. Furthermore, 
quercetin (1) has been isolated from ClEtOH through 
classical column chromatographic fractionation (Araujo, 
2012) and identified by 1H and 13C NMR experiments and 
comparison with literature data (Adeyemi et al., 2010) and 
an authentic sample.
Quercetin (1): (256 mg; 0.039 %) yellow crystals, mp. 
318-319 °C (315°C; [29]), 1H NMR (500 MHz, CD3OD): 
7.75 (d, J2’,6’ 2.05 Hz, H-2’), 7.65 (dd, J6’,2’ 2.05 Hz and J6’,5’ 
8.5 Hz, H-6’), 6.90 (d, J5’,6’ 8.5 Hz, H-5’), 6.40 (d, J8,6 1.95 
Hz, H-8), 6.20 (d, J6,8 1.95 Hz, H-6). 
13C NMR (125 MHz, 
CD3OD): 147.4 (C-2), 135.8 (C-3), 175.9 (C-4),  161.1 
(C-5), 97.8 (C-6), 164.2 (C-7), 93.0 (C-8), 156.8  (C-4a), 
103.1 (C-8a), 122.7 (C-1’), 114.6 (C-2’), 144.8 (C-3’), 
146.6 (C-4’), 114.8 (C-5’), 120.3 (C-6’).
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 In the acute toxicity assay, it was demonstrated 
that the treatment with ClEtOH in doses ranging from 100 
to 5,000 mg/kg did not promote any behavioral changes 
or mortality in animals. The doses of 250 and 500 mg/kg 
were selected for the evaluation of the antidiabetic activity 
of ClEtOH in the subchronic experiment.  
Figure 1. A. Chromatographic profile of Combretum 
lanceolatum flowers ethanolic extract (ClEtOH); B. quercetin 
standard; and C. ClEtOH with quercetin standard. Analysis in 
HPLC-UV with detection at 368 nm.
Improvement in body and tissues weights of diabetic rats 
treated with ClEtOH
 Body weight
 At the beginning of the experiment, rats from 
different groups showed similar body weight values. The 
treatment of diabetic rats with 500 mg/kg of ClEtOH 
promoted a 2-fold increase in the diary body weight gain 
when compared to DC group (Table 1), leading to an increase 
(21%) in the final body weight (Table 1, Figure 2A). The 
body weight in DT500 group was higher in comparison 
to the beginning since the 12th day of treatment until the 
end of the experiment. Although the animals treated with 
metformin or with 250 mg/kg of ClEtOH presented a daily 
body weight gain significantly higher than controls, the 
final body weight of animals from these groups was not 
statistically different of values from untreated animals 
(Table 1, Figure 2A).
 Weight of peripheral tissues
 It was observed an increase of 20% in the 
weight of liver from diabetic rats treated with ClEtOH, 
in both doses, as well as in metformin-treated rats, when 
compared to DC. The treatment of diabetic rats with 500 
mg/kg of ClEtOH also promoted increase in the weight 
of epididymal (92%) and retroperitoneal (4-fold) adipose 
tissues and of soleus (28%) and EDL (29%) muscles (Table 
2), which corroborated with the increased body weight 
gain of animals from DT500 group.
Reduction on food intake, liquid intake and urinary volume 
of diabetic rats treated with ClEtOH
 There were no changes in the daily values of 
food and water intake or urinary volume between DT250 
and DC groups (Table 1). The treatment with 500 mg/
kg of ClEtOH promoted decrease of 14, 33 and 39%, 
respectively, in daily food intake, water intake and urinary 
volume in comparison to DC group (Table 1, Figure 2B, 
2C and 2D). As expected, the metformin-treated rats also 
presented a decrease in daily values of food and water 
ingestion and of urinary volume in comparison to controls. 
The food and water ingestion and the urinary volume of 
diabetic rats treated with 500 mg/kg of ClEtOH were not 
different to values of metformin-treated rats, showing 
that plant extract improved these parameters likewise 
metformin.
Treatment with ClEtOH ameliorates biochemical 
parameters of diabetic rats
 Plasma glucose
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 Prior to treatment beginning, all the groups 
presented blood glucose levels at very similar values (DC = 
493.0±17.6; DMet = 505.4±56.36; DT250 = 473.3±17.22; 
DT500 = 484.9±27.77, mg/dL, n=8-9 animals). At the end 
of the treatment, diabetic animals that received ClEtOH 
presented a reduction of 16% (250 mg/kg) and 22 % 
(500 mg/kg) in the glycemia levels when compared to 
non-treated rats. As expected, the glycemia levels were 
also reduced in diabetic rats treated with metformin, in 
comparison to DC and DT250 groups (DC = 505.6±17.50; 
DMet = 338.4±13.53; DT250 = 426.8±6.62; DT500 = 
391.6±21.13, mg/dL, n=8-9 animals). It is important to 
highlight that the glycemia values from DT500 and DMet 
groups were similar at the end of the experiment. In the 
same way, the area under the curve (AUC) of glycemia 
from DMet, DT250 and DT500 groups were also lower 
than controls (Figure 3).
Table 1. Values of body weight, food intake, water intake and urinary volume from diabetic rats treated during 21 days with 500 
mg/kg of metformin (DMet) and with 250 (DT250) or 500 mg/kg (DT500) of Combretum lanceolatum flowers ethanolic extract. 
DC (n= 8) DMet (n= 9) DT250 (n=9) DT500 (n=8)
Initial body 
weight (g) 203.7±3.91 200.0±7.64 213.2±3.77 199.2±14.03
Final body 
weight (g) 235.4±6.03 269.9±11.66 264.8±7.08 283.7±12.19
**
Daily weight 
gain (g) 1.45±0.30 3.33±0.41
** 2.60±0.32* 3.44±0.35**
Daily food 
intake (g) 35.1±1.12 25.3±0.84
** 34.9±1.40## 30.1±1.64*
Daily water 
intake (mL) 151.3±10.70 64.1±6.60
** 142.3±10.79## 100.7±13.03*
Daily urinary 
volume (mL) 109.2±9.61 36.8±8.31
** 105.1±8.15## 66.1±12.11*,##
Values represent mean±SEM; n: number of animals; *p< 0.05 and **p<0.01 vs DC; ##p<0.01. vs DMet.
Figure 2. Physiological parameters of diabetic rats non-treated (DC) and treated during 21 days with 500 mg/kg of metformin 
(DMet) and with 250 (DT250) or 500 mg/kg (DT500) of Combretum lanceolatum flowers ethanolic extract. A. Body weight, 
g; B. food intake, g; C. water intake, mL; D. urinary volume, mL. Each point represents mean±SEM of 8-9 animals. *p<0.05 
and **p<0.01 vs DC; ##p<0.01 vs DMet.
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Figure 3. Plasma glucose levels (mg/dL) during the experiment 
(A) and area under the curve of glycemia (B) from diabetic rats 
non-treated (DC) and treated during 21 days with 500 mg/kg of 
metformin (DMet) and with 250 (DT250) or 500 mg/kg (DT500) 
of Combretum lanceolatum flowers ethanolic extract. Each point 
represents mean±SEM of 8-9 animals. *p<0.05 and **p<0.01 vs 
DC.
 Glycosuria and urinary urea
 At the end of the experiment, the urinary glucose 
(Figure 4) and urea levels (Figure 5) of diabetic rats treated 
with 500 mg/kg of ClEtOH were, respectively, 43% and 
38% lower than values from diabetic non-treated rats. 
The glycosuria and urinary urea levels from diabetic rats 
treated with 250 mg/kg of ClEtOH were not different of 
values from DC group. As expected, the glycosuria values 
from rats treated with metformin were also lower than 
values from DC and DT250 groups, as well as the urinary 
urea levels (Figures 4 and 5). There were no differences 
in the urinary glucose and urea levels between DT500 
and DMet groups. The AUC of glycosuria and urinary 
urea from diabetic rats treated with 500 mg/kg of ClEtOH 
were, respectively, 32% and 23% lower than values from 
DC group (Figures 4 and 5).
Figure 4. Urinary glucose levels (g/24h) during the experiment 
(A) and area under the curve of urinary glucose (B) from diabetic 
rats non-treated (DC) and treated during 21 days with 500 mg/
kg of metformin (DMet) and with 250 (DT250) or 500 mg/kg 
(DT500) of Combretum lanceolatum flowers ethanolic extract. 
Each point represents mean±SEM of 8-9 animals. *p<0.05 vs 
DC; #p<0.05 vs DMet.
Table 2. Weight of white adipose tissues (epididymal, retroperitoneal and perirenal), skeletal muscles (EDL and soleus) and 
liver from diabetic rats treated during 21 days with 500 mg/kg of metformin (DMet) and with 250 (DT250) or 500 mg/kg 
(DT500) of Combretum lanceolatum flowers ethanolic extract.
DC (n= 9) DMet (n= 8) DT250 (n=8) DT500 (n=8)
Epididymal (g) 0.920±0.116 1.871±0.244** 1.334±0.091 1.765±0.228**
Retroperitoneal (g) 0.278±0.077 1.210±0.274* 0.733±0.111 1.116±0.260*
Perirenal (g) 0.146±0.074 0.240±0.054 0.132±0.017 0.254±0.064
EDL (g) 0.209±0.008 0.242±0.021 0.244±0.008 0.270±0.026*
Soleus (g) 0.252±0.012 0.269±0.012 0.279±0.018 0.322±0.019*
Liver (g) 10.78±0.293 12.83±0.782* 12.90±0.406* 12.67±0.687*
Values represent mean±SEM; n: number of animals; *p<0.05 and **p<0.01 vs DC.
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Figure 5. Urinary urea levels (g/24h) during the experiment (A) 
and area under the curve of urinary urea (B) from diabetic rats 
non-treated (DC) and treated during 21 days with 500 mg/kg of 
metformin (DMet) and with 250 (DT250) or 500 mg/kg (DT500) 
of Combretum lanceolatum flowers ethanolic extract. Each point 
represents mean±SEM of 8-9 animals. *p<0.05 and **p<0.01 vs 
DC; #p<0.05 vs DMet.
 Liver glycogen content
 The liver glycogen content was 90% higher 
in diabetic animals treated with 500 mg/kg of ClEtOH 
in comparison to DC group (DC = 11.36±1.17; DMet = 
19.00±4.42; DT250 = 20.39±4.62; DT500 = 21.58±4.21, 
mg/g, n = 8-9 animals).
ClEtOH promotes in vitro AMPK activation in rat liver 
slices
 As expected, the incubation of liver slices with 
50 μg/ml metformin promoted an increase (23%) in 
the phosphorylation levels of AMPK. There was also 
observed a 29% raise in the AMPK phosphorylation when 
liver slices were incubated with 10 μg/mL quercetin. 
Incubation of liver slices with 50 μg/mL of ClEtOH 
resulted in an increase in the phosphorylation levels of 
AMPK (31%) in a similar magnitude of that observed to 
metformin or quercetin. No changes were observed in the 
AMPK phosphorylation after incubation with metformin, 
quercetin and ClEtOH in the doses of 10, 50 and 100 μg/
mL, respectively (Figure 6).
 
Figure 6. Phosphorylation levels of AMPK (% of basal values) 
in liver slices incubated in the presence of metformin [10 μg/mL 
(Met10) and 50 μg/mL (Met50)], quercetin [10 μg/mL (Querc10) 
and 50 μg/mL (Querc50)] and Combretum lanceolatum flowers 
ethanolic extract [50 μg/mL (ClEtOH50) and 100 μg/mL 
(ClEtOH100)]. Values are means±SEM of 3-5 liver slices. *p< 
0.05  basal.
Discussion
 Crescent attention has been given to the 
investigation of the antidiabetic activity of many plant 
species all around the world, using different experimental 
models and several methodologies. However, information 
about the safety of plant-derived medicines is essential, 
considering that medicinal plants are easily acquired by 
the population and that many toxicological effects may 
be observed after the use of herbal preparations. In this 
way, it is common the use of mice in the experimental 
investigation of the acute toxic effects of plant extracts 
orally administered in high doses (Mu et al., 2011; 
Jesus et al., 2012). Data from this study showed that the 
Combretum lanceolatum Pohl ex Eichler, Combretaceae, 
extract did not have any acute toxicity in animals, at every 
tested dose. In front of the lack of toxicity, the doses of 
250 and 500 mg/kg were chosen to the evaluation of the 
antidiabetic activity of C. lanceolatum flower extract in 
STZ-diabetic rats.
 In insulin deficiency and/or resistance conditions, 
the hyperglycemia is a consequence of the combination 
of increased endogenous glucose production, related to 
the higher rates of glycogenolysis and gluconeogenesis 
processes, and reduced glucose uptake by peripheral 
tissues. It has been proposed that the search and/or 
development of new compounds that correct these glucose 
metabolism disturbances will be important to highlight 
new options for diabetes treatment (Wu et al., 2005; Leney 
& Tavaré, 2009).
 Specifically to gluconeogenesis, it is well known 
that insulin deficiency lead to a marked skeletal muscle 
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proteolysis, increasing the flow of amino acids into the 
liver and providing substrates to gluconeogenesis. Since 
our results showed a reduction in the urinary urea values 
(Figure 5) and an increase in the weight of soleus and EDL 
skeletal muscles (Table 2), it is reasonable to speculate that 
the improvement in the carbohydrate metabolism of diabetic 
rats treated with C. lanceolatum could be explained, at least 
in part, by a decrease in the rate of hepatic gluconeogenesis, 
modulating the activity and/or gene expression of the 
rate-limiting enzymes of gluconeogenesis, as example 
phosphoenolpyruvate carboxykinase (PEPCK) and/or 
glucose-6-phosphatase (G6Pase). If C. lanceolatum extract 
exerts an antidiabetic activity through gluconeogenesis 
inhibition, its action can be related to that promoted by 
metformin, a classical hypoglycemic drug that lead to 
gluconeogenesis inhibition (Hundal & Inzucchi, 2003). 
Recent findings have described that the hypoglycemic 
effect of metformin occurs through activation of adenosine 
monophosphate-activated protein kinase (AMPK), a 
serine/threonine protein kinase that exerts a central role in 
the regulation of cellular metabolism and energy balance 
(Hardie, 2007). Indeed, it was demonstrated that metformin 
downregulates PEPCK and G6Pase expression through 
liver AMPK activation (Lochhead et al., 2000; Zhou et al., 
2001). Nowadays, AMPK activation has been pointed as 
a potential target for the treatment of diabetes and other 
metabolic disorders (Towler & Hardie, 2007; Viollet et al., 
2007). In addition, the search of natural compounds that 
activate this kinase showed that some polyphenols activate 
AMPK during its beneficial effects on metabolic disorders, 
as example quercetin (Aguirre et al., 2011), curcumin 
(Aggarwal, 2010), epigallocatechin-3-gallate (Collins et 
al., 2007) and resveratrol (Shin et al., 2009). Therefore, it 
can be suggested that polyphenols are potential candidates 
of natural origin to diabetes treatment (Hwang et al., 
2009), because they stimulate a cellular target similar 
to that of metformin. Corroborating with this, data from 
this study showed that AMPK phosphorylation levels 
were increased in liver slices incubated in the presence 
of C. lanceolatum extract (Figure 6) in a similar way 
of that observed with quercetin or metformin, showing 
that the antihyperglycemic effect of the extract could be 
attributed, at least in part, to AMPK stimulation followed 
by inhibition of gluconeogenesis process. Confirming this 
hypothesis, our results also demonstrated that the in vivo 
beneficial effects of the extract on several parameters were 
very similar to that promoted by metformin, as example 
reduction on glycemia (Figure 3), glycosuria (Figure 
4) and urinary urea (Figure 5). Current investigations 
have been carried out in our laboratory to confirm if the 
in vivo AMPK activation is involved in the inhibition 
of hepatic gluconeogenesis by C. lanceolatum extract, 
through the analysis of the AMPK phosphorylation in 
liver from diabetic rats treated with the extract, as well as 
the changes in the PEPCK expression and in the hepatic 
glucose production (Siqueira et al., 2012). Taken together, 
it is believed that quercetin, identified and isolated from 
C. lanceolatum extract (Figure 1), activates AMPK in 
vivo, contributing to the treatment of diabetes symptoms. 
Corroborating our findings, quercetin has been reported 
to be the active compound that explains the antidiabetic 
activity of some plant species (Eid et al., 2010; Veerapur et 
al., 2010). In fact, both in vivo and in vitro studies performed 
with quercetin have also demonstrated the beneficial 
effects of this flavonoid on several parameters altered in 
diabetes (Aguirre et al., 2011). In this way, the isolation 
of a potential antidiabetic compound in C. lanceolatum 
extract, together with the beneficial effects observed in 
STZ-diabetic rats treated with the extract reinforces our 
purpose, focused in the continuity of the studies with C. 
lanceolatum, obtaining sufficient data to justify its future 
indication into phytotherapic formulations to treat diabetes 
symptoms.
 Because liver glycogen content was increased in 
diabetic rats after C. lanceolatum treatment, it is possible 
that the extract promotes decrease in liver glycogenolysis 
and/or increase in glycogenesis. In addition, since the 
extract treatment also promoted increase in the weight 
of adipose tissues (Table 2) and reduction in the food 
intake (Figure 2B) of diabetic rats, similar to metformin 
effects, it can be suggested that the extract promotes a 
better glucose disposal by peripheral tissues. Considering 
that quercetin, found in the extract, stimulates AMPK, a 
probable beneficial effect on glucose uptake promoted 
by C. lanceolatum can be referred as a metformin-like 
response, since this hypoglycemic drug stimulates glucose 
transporter type 4 (GLUT4) translocation to plasma 
membranes of peripheral tissues in an AMPK-dependent 
manner (Lee et al., 2011). These possibilities of the extract 
actions are the focus of current studies.
 In summary, the findings of the present study 
indicated that the ethanolic extract of C. lanceolatum 
flowers has antihyperglycemic activity, as well as that 
quercetin is the major compound in the extract. The 
antidiabetic effect of C. lanceolatum can be attributed, at 
least in part, to the AMPK activation in liver by quercetin, 
in a similar manner of metformin, inhibiting hepatic 
glucose production. Further investigations are ongoing 
in our laboratory to detail the mechanisms of action that 
explains the antidiabetic effect of this plant extract. 
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